|Bid||29.42 x 200|
|Ask||32.60 x 1000|
|Day's Range||30.22 - 31.70|
|52 Week Range||25.06 - 41.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.75|
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2017 on Tuesday, February 27, 2018, after the U.S.
The Soros Fund Management reportedly sold its entire holdings of Acadia Pharmaceuticals and Shire plc in the fourth quarter of 2017.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Umpqua ...
NEW YORK, NY / ACCESSWIRE / February 6, 2018 / The markets recent selloff continued Monday as a result of rising interest rates. Both the Dow Jones and the S&P 500 fell sharply to close in negative territory ...
Stocks with market capitalization between $2B and $10B, such as ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) with a size of $3.34B, do not attract as much attention from the investing community asRead More...
The downtrend in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) may end soon — not from the renewed interest in biotech stocks but because of Aurina’s upcoming revenue potential. Aurina has a potential blockbuster drug, called Voclosporin, that is in the clinical stages. AUPH’s priorities during both its second and third quarter were the Aurora Phase III trial.
NEW YORK, NY / ACCESSWIRE / January 9, 2018 / It was a day of losses for ACADIA on Monday, closing the day down a little over 6% at $27.11. There was no major news from the company whose stock was trading ...
I am going to run you through how I calculated the intrinsic value of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) using the discounted cash flow (DCF) method. If you want to learnRead More...
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 36th Annual J.P.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ACADIA Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACAD-US. Comparing the performance and risk of ACADIA Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Over the last month, growth of ETFs holding ACAD is favorable, with net inflows of $10.10 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for ACADIA Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.
Categories: Yahoo FinanceGet free summary analysis ACADIA Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ACADIA Pharmaceuticals, Inc. – Vanda Pharmaceuticals Inc., Catalyst Biosciences, Inc., Pfizer Inc. and Adamas Pharmaceuticals, Inc. (VNDA-US, CBIO-US, PFE-US and ADMS-US) that have also reported for this period. ... Read more (Read more...)